CN Patent

CN107126563B — 含低剂量阻断vegf信号通路的抗体的组合物及其用途

Assigned to Perongen Biotherapeutics Suzhou Co ltd · Expires 2021-09-10 · 5y expired

What this patent protects

本发明提供了一种含低剂量VEGF信号通路阻断剂的组合物及其用途。具体地，本发明提供了低剂量的VEGF信号通路阻断剂在用于制备肿瘤免疫治疗促进剂中的用途，以及含有低剂量VEGF信号通路阻断剂的组合物。本发明的实验表明，低剂量的VEGF信号通路阻断剂，能够诱导肿瘤血管的正常化，显著提高肿瘤免疫治疗的效果，并能促进T淋巴细胞对肿瘤组织的浸润。

USPTO Abstract

本发明提供了一种含低剂量VEGF信号通路阻断剂的组合物及其用途。具体地，本发明提供了低剂量的VEGF信号通路阻断剂在用于制备肿瘤免疫治疗促进剂中的用途，以及含有低剂量VEGF信号通路阻断剂的组合物。本发明的实验表明，低剂量的VEGF信号通路阻断剂，能够诱导肿瘤血管的正常化，显著提高肿瘤免疫治疗的效果，并能促进T淋巴细胞对肿瘤组织的浸润。

Drugs covered by this patent

Patent Metadata

Patent number
CN107126563B
Jurisdiction
CN
Classification
—
Expires
2021-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Perongen Biotherapeutics Suzhou Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.